
HC Wainwright & Co. has decided to maintain its Buy rating of Aerie Pharmaceuticals (NASDAQ:AERI) and lower its price target from $25.00 to $20.00.
Shares of Aerie Pharmaceuticals are trading down 3.54% over the last 24 hours, at $6.03 per share.

HC Wainwright & Co. has decided to maintain its Buy rating of Aerie Pharmaceuticals (NASDAQ:AERI) and lower its price target from $25.00 to $20.00.
Shares of Aerie Pharmaceuticals are trading down 3.54% over the last 24 hours, at $6.03 per share.